Translate Bio Overview
- Founded
-
2010

- Status
-
Acquired/Merged
- Employees
-
122

- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$3.04B
Translate Bio General Information
Description
Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.
Contact Information
Website
www.translate.bio
Formerly Known As
RaNA Therapeutics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Office
- 29 Hartwell Avenue
- Lexington, MA 02421
- United States
Translate Bio Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
8. Merger/Acquisition | 14-Sep-2021 | $3.04B | 00000 | 00.00 | Completed | Generating Revenue/Not Profitable |
7. PIPE | 20-Jul-2020 | 00000 | 00000 | Completed | Generating Revenue/Not Profitable | |
6. 2PO | 18-Sep-2019 | 0000 | 00000 | Completed | Generating Revenue | |
5. PIPE | 03-May-2019 | 000.00 | 00000 | Completed | Generating Revenue | |
4. IPO | 28-Jun-2018 | 00000 | 00000 | 00000 | Completed | Generating Revenue |
3. Later Stage VC (Series C) | 04-Jan-2017 | 0000 | 00000 | Completed | Generating Revenue | |
2. Early Stage VC (Series B) | 30-Jul-2015 | $63.8M | $90M | Completed | Startup | |
1. Early Stage VC (Series A) | 18-Jan-2012 | $20.7M | $20.7M | 000.00 | Completed | Startup |
Translate Bio Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A | 00,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00.000 |
Translate Bio Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative med
Drug Discovery
Lexington, MA
122
As of 2020
00000
0.00
0000-00-00
000000&0
00000
Translate Bio Competitors (79)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Selecta Biosciences | Formerly VC-backed | Watertown, MA | 00 | 00000 | 000000000 | 00000 |
00000000 000000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000000 - | 00000 |
000 00000000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000000 | 00000 |
0000000 | Corporation | Monmouth Junction, NJ | 00 | 00000 | 00000000 | |
00000 000000000000 | Formerly VC-backed | Waltham, MA | 000 | 00000 | 00000000 | 00000 |
Translate Bio Patents
Translate Bio Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20220287966-A1 | Stable liquid lipid nanoparticle formulations | Pending | 25-Nov-2020 | 0000000000 | |
US-20220160633-A1 | Compositions for delivery of codon-optimized mrna | Pending | 09-Nov-2020 | 0000000000 | |
US-20220136022-A1 | Large scale synthesis of messenger rna | Pending | 15-Oct-2020 | 000000000 | |
US-20220133631-A1 | Process of preparing ice-based lipid nanoparticles | Pending | 12-Oct-2020 | 0000000000 | |
US-20220110884-A1 | Process of preparing mrna-loaded lipid nanoparticles | Pending | 12-Oct-2020 | A61K9/5192 |
Translate Bio Executive Team (19)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Ronald Renaud Jr. | Chief Executive Officer |
Translate Bio Board Members (16)
Name | Representing | Role | Since |
---|---|---|---|
Daniel Lynch | Self | Chairman & Board Member | 000 0000 |
Jean-Francois Formela MD | Self | Board Member | 000 0000 |
Owen Hughes Jr. | Self | Board Member | 000 0000 |
Ronald Renaud Jr. | Translate Bio | Chief Executive Officer | 000 0000 |
Translate Bio Signals
Translate Bio Former Investors (15)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Atlas Venture | Venture Capital | Minority | 000 0000 | 000000 0 | |
Brookside Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
Fidelity Investments | Mutual Fund | Minority | 000 0000 | 000000 0 | |
Frazier Healthcare Partners | PE/Buyout | Minority | 000 0000 | 000000 0 | |
Leaps by Bayer | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |
Translate Bio Investments (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000 (000 00 | 04-Jan-2017 | 000000000 | 00000 | Buildings and Property | 000000 00 |